NCT02428712: A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors

NCT02428712
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRAF
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: Child, Adult), Senior)
Location of Metastases: 
Additional Notes: Only patients with BRAF+ solid tumors will be eligible for phase 2
Exclusions: 
https://ClinicalTrials.gov/show/NCT02428712

Comments are closed.

Up ↑